Entering text into the input field will update the search result below

Caladrius Snatches Itself A Clinical Candidate For Heart Disease


  • Caladrius Biosciences adds late-stage cell therapy treatment for heart disease to its pipeline.
  • The CD34+ cell therapy treatment was licensed from Shire.
  • The purchase of the CD34+ program was based on positive data stemming from multiple clinical trials proving that the drug works in the intended population.
  • Caladrius states it has enough cash past 2018, but a cash raise will likely be needed before the end of 2018.
  • It is highly likely that the company may have to run its own phase 3 study to confirm clinical findings before it can file for regulatory approval for the newly acquired CD34+ cell therapy.

Shares of Caladrius Biosciences (CLBS) closed higher by 9% on Tuesday, after it announced that it had acquired rights to a heart disease drug. This adds a late-stage drug to the pipeline which is why I believe that Caldrius is an excellent buy.

Licensing Deal

Caladrius Biosciences acquired the rights to license the drug from Shire (SHPG) under a licensing deal. According to the deal Caladrius will have to pay an upfront payment which has not yet been disclosed. In addition, Shire will be eligible to receive milestone payments and royalties based on net sales of the product should it reach the market. More specifically, Caladrius has been able to get its hand on an asset that has already completed multiple placebo controlled studies. This involves the CD34+ cell therapy program for the treatment of refractory angina. The data set that has been obtained by Caladrius for this purchase is pre-clinical, phase 1, phase 2, and phase 3 clinical study data. In my opinion, this was a smart buy for Caladrius. That's because it now has its hands on a late-stage asset. Sure, it had to give up some cash for it and give up royalty payments for it. That doesn't change the fact that this adds a late-stage asset to its pipeline.

Purchase Based On Data

It is sometimes seen that pharmaceutical companies acquire earlier stage assets just based on pre-clinical data, and hope that a drug will succeed. This is a good opportunity for Caladrius. That's because it acquired the drug based on multiple positive studies done in over 300 patients. The data from all three studies are quite good. Results were good for two reasons. The first being that they were published in the European Heart Journal under the title "Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical investment research service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to my Service, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers deep dive analysis of many pharmaceutical companies throughout the biotech sector. Come see for yourself if my service is right for you.

New Promotion Pricing: The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

Author's note: To get these types of premium articles on attractive biotech and pharma stocks as soon as they are published, just click here for my profile. Hit the big orange "Follow" button and choose the real-time alerts option thank you for taking the time to read my analysis

This article was written by

Terry Chrisomalis profile picture

I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha.

You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (9)

Bio Surfer profile picture
After reading the article as well as all the comments, my view on this company:

1) if it is a great drug why shire wanted to sell
2) the management team got to change, not good enough
3) mis judgement in history will likely to repeat in the future

so, not very good opportunities here
Those who got burned on this one might want to do some research on ATHX. I invested in both at the same time and it seems ATHX management has a bit more of a clue on both the science and the business of bringing a stem cell product to market. There have been some particularly interesting developments on the stock in the past week. I'm down but not out and unlike with CLBS I think there is a reasonable probability of an enormous payday if I stick it out a few more years.
Wait for the dilution. It is a given with their history. I was also with Neostem from the early days, through China, then Japan and a host of University presentations until today. Always the same. They seem to short their own stock with junk public offerings pumped with clinical trial promises to raise capital to complete research just on the brink of break through success. If you wait, they will make a stock offering at a discount rate to raise its finances sooner than later. I suggest you benchmark this at the 52 week low area. That's where it will bounce back from for another ride through the treadmill. It would be nice if they cured peridontal disease with some simple application of stem cell therapy after all this time. But the big lure is hearts and minds; and those stem cells seem to be from cash cow market samplings. Bitter? You bet!
From 2010 up until at least 2013-2014, the Catholic Church was involved in Neostem, as well. They may have bailed out at some point between then and now, or between Neostem and Caladrius. I don't know.

I can't determine either way. If you or anyone else can, please let me know.
Investing in this stock was one of my biggest failures. I got in back when they were Neostem primarily because I thought they might have a future in manufacturing/processing. They got out of that business. Poor management, bad decisions, extreme dilution of the stock. The only reason I continue to hold is that I've already lost all my money so might as well bank on the million to one chance of a clinical success. Valuable lessons learned on investing in stem cell as the next big thing. The risk of bringing something like this to market without serious dilution are great. I would stay away.
JJPP profile picture
08 Mar. 2018
Ah yes, the good old days when Robin would have her investor calls and promise the world based on the current clinical trials which all failed with the exception of the Type 1 diabetes study currently in ph2. I also invested in Neostem for their CD34+ product to repair heart damage after an MI. Lost most of my investment too.
NDHT profile picture
Felt like I thought that I had just got a rare disease, thinking why I am the only unlucky one? But when I went to see the doctor, there is a long line of patients waiting there to see him/her. Jokingly kind of felt better to see I am not alone here :-)

To be fair, those dark days were made by the previous management. Hope the new team will make a difference.
JJPP profile picture
07 Mar. 2018
One of my concerns here is that previous CD34+ studies in CV trials all seem to have performed well in early stage however the vast majority, if not all, have failed to make it to the NDA stage. I am not educated enough on CD34+ to start to dissect the clinical differences between the trials, disease states in which they have been studied, and outcome data however it is a point of concern to a potential investor like myself. I believe their own CD34+ and Baxter's 34CD+ trials from a few years ago failed miserably but those studies were not for angina.
Long CLBS, fingers crossed for the future.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.